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The epidemics of overweight and obesity has resulted in a significant increase of non alcoholic fatty liver disease
(NAFLD), a potentially progressive condition. Currently, obesity related hepatopathy represents therefore the main
cause of pediatric chronic liver disease. The first choice treatment at all ages is weight loss and/or lifestyle changes,
however compliance is very poor and a pharmacological approach has become necessary. In the present article we
present a systematic literature review focusing on established pediatric NALFD drugs (ursodeoxycholic acid, insulin
sensitizers, and antioxidants) and on innovative therapeutic options as well.
Regarding the former ones, a pediatric pilot study highlighted that ursodeoxycholic acid is not efficient on
transaminases levels and bright liver. Similarly, a recent large scale, multicenter randomized clinical trial (TONIC
study) showed that also insulin sensitizers and antioxidant vitamin E have scarce effects on serum transaminase
levels. Among a large series of novel therapeutic approaches acting on recently proposed different
pathomechanisms, probiotics seem hitherto the most interesting and reasonable option for their safety and
tolerability. Toll-like receptors modifiers, Pentoxifylline, and Farnesoid X receptors agonists have been still poorly
investigated, and will need further studies before becoming possible promising innovative therapeutic strategies.
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Non alcoholic fatty liver disease is nowadays the most
common cause of chronic liver disease also in pediatric
age, as a result of the increasing prevalence of childhood
obesity. It represents a spectrum of liver diseases ranging
from simple steatosis to steatohepatitis, with, in some
cases, possible fibro/cirrhotic progression, thus increas-
ing liver-related morbidity and mortality [1]. The main-
stay of NAFLD therapy is represented by lifestyle
interventions on obesogenic environment and sedentary
life, which aim to improve obesity, obesity-related hep-
atic changes, and quality of life as well [2]. Unfortunately
this target is difficult to be achieved, and results are un-
satisfactory. In fact, only a little proportion of individuals
is really able to steadily lose weight and to practice* Correspondence: pvajro@unisa.it
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reproduction in any medium, provided the orphysical exercises [1]. No agreement exists on NAFLD
management of obese children who result not-compliant
to prescriptions. Since several established pathogenetic
mechanisms (in particular insulin resistance, oxidative
stress, and apoptosis) seem to be involved in NAFLD, a
number of therapeutic agents targeting these mechan-
isms (Figure 1) have been tested not only in animal
models but also in human adults and in children. Results
however are still puzzling and/or unsatisfactory [1,3].
The aim of this article is to review current NAFLD
treatments and possible novel options in the pediatric
age group, by providing recent evidences from literature.Materials and methods
Search strategy and inclusion criteria
Through the MEDLINE database we searched for articles
on NAFLD treatment in pediatric age appearing from
1st May 2009 (date of publication of the meta-analysis
of Socha et al. [3]) to 1st August 2012. No languaged. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and



































Figure 1 NAFLD pathogenesis-driven old and novel potential treatments in pediatric NAFLD/NASH. Symbols: * current , ** potential, and/
or *(*) partially established therapeutic approaches in pediatric NAFLD. ABBREVIATIONS DHA, docosahexanoic acid; DPP-4, dipeptidyl peptidase-4;
FFA, free fatty acid; FXR, farnesoid X receptor; NAFLD, non alcoholic fatty liver disease; NASH, non alcoholic steatohepatitis; TLR, toll-like receptor;
UDCA, ursodeoxycholic acid.
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articles on NAFLD therapy in pediatric age were
reviewed. When paucity/absence of pediatric data were
evident we retrieved also articles on NAFLD therapy in
adults. The electronic literature search was performed
using the following keywords which had been suggested
by previous manual search: NAFLD, NASH, fatty liver,
treatment and/or therapy, lifestyle interventions, weight
loss, physical activity, antioxidant and/or vitamin E,
metformin and/or insulin sesitizers, ursodeoxycholic
acid, probiotics and prebiotics, omega-3-fatty acid and/
or docosahexaenoic acid, bariatric surgery, toll like
receptors modifiers, pentoxifylline, farnesoid X receptor
agonist, incretin mimetics, dipeptidyl peptidase-4 inhibi-
tors, angiotensin-converting enzyme (ACE) inhibitors,
angiotensin-receptor blockers (ARBs), children, adults,
animal model. Title and abstract of each retrieved refer-
ence was screened by one author. Full papers were
screened independently by two researchers. Discrepan-
cies between reviewers were resolved by consensus. Anarrative review of novel and old therapeutic strategies
was conducted.
Data extraction
Data were collected by using a data extraction form.
Studies were collected for old/present and novel/
potential pharmacological strategies both in children




Weight reduction in NAFLD patients reduces the deliv-
ery of free fatty acids (FFA) to the liver, improving extra-
hepatic insulin sensitivity by means of a better peripheral
glucose utilization. Furthermore it promotes a reduction
of reactive oxygen substances (ROS) and adipose tissue
inflammation [4].
Recent studies confirmed an amelioration in transami-
nases levels and in several metabolic parameters (lipids,
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pediatric age [5-8].
A sucrose-rich diet (e.g. soft-drinks) increases the hep-
atic synthesis of triglycerides: rats and humans that are
fed either sucrose or fructose enriched diets develop
fatty and fibrotic liver. Fructose reduction may decrease
insulin resistance (IR) and lipogenesis, and also hepatic
pro-inflammatory/fibrogenetic effects [9].
Other helpful proposed dietetic measures include the
reduction of dietary intake of satured/trans fat, increased
intake of fibers [10] and a higher intake of polyunsatur-
ated fat (omega-3) [11].
Weight loss (target= approximately 5-10% of basal
weight) should be achieved gradually, since extreme slim-
ming diets may lead to the onset of severe metabolic disor-
ders and promote liver histological damage. Dietary
interventions are still not based on precise evidence-based
guidelines: in childhood however diets must be balanced
to allow a healthy and harmonic growth [12]. The
ESPGHAN Committee on Nutrition [13] suggests that en-
ergy intake should be individually determined, and slowly
rather than rapidly absorbed carbohydrates should be pre-
ferred. A clinical approach in older children should consist
in a weight loss of about 500 g / week. In younger children
one might suggest even to simply not gain further weight
in order to improve the weight-height ratio, and also to im-
prove waist circumference (i.e. the most sensitive marker of
visceral obesity and its related liver involvement) [7,14].
Physical activity
Physical activity should be integrated in NAFLD therapy
because of its beneficial effect independent of weight loss,
by enhancing insulin sensitivity and glucose homeostasis
[15]. Exercise has a beneficial effect also on FFA metabol-
ism, by enhancing whole-body lipid oxidation [16] and de-
creasing hepatic triglyceride accumulation [17].
In obese adolescents a three-month resistance exercise
program, which involved all major muscle groups 2 × 1
h/week, resulted in significant strength and lean body
mass gain. Although hepatic fat content remained fairly
stable, hepatic insulin sensitivity increased and glucose
production rate decreased, without weight loss [18].
Despite aerobic exercise seems to have more extensive
effects, a longer duration and/or a more intensive resist-
ance exercise program may be required for reduction of
hepatic fat content. For those who have physical limita-
tions and/or low motivation that prevent them from per-
formance of aerobic activity, resistance exercise can
serve as an alternative option.
Lifestyle changes should include all family members to
increase compliance, along with a multidisciplinary ap-
proach, including childhood dedicated dietician and
psychologist. Pediatricians and pediatric gastroentero-
hepatologists should have a leading role in the casemanagement of pediatric NAFLD, working with other
professional specialties involved in physical and intellec-
tual growth [9].
Since treatment options are nowadays still limited,
obesity prevention should still be the optimal strategy in
the management of NAFLD. In view of the poor adher-
ence to diets and exercise, novel strategies have also
been envisaged, including “e-health platforms”. These
are aimed at improving treatment compliance and pro-
moting the mechanisms of patients self-control, to ob-
tain weight loss maintenance, and to prevent relapse by
establishing healthy lifestyle habits [19].
Drug treatments for NAFLD in pediatric age
When diet and/or exercise are not obtainable, a pharma-
cological approach acting upon one or more specific tar-
gets involved in NAFLD aetiopathogenesis should be
used (Figure 1). Insulin sensitizers, antioxidants and
cytoprotective agents are the drugs which have hitherto
been more extensively used.
Insulin sensitizers
Hepatic insulin resistance has been highlighted in most
of the children/adolescents with NAFLD [20]. Even if
the molecular mechanism is poorly understood, insulin
resistance has a key role in NAFLD by promoting the
storage of FFA. For this reason it might be considered
an advantageous therapeutic target [1]. The only insulin-
sensitizer which has been well evaluated in pediatric
NAFLD is metformin. A pilot study in 10 non diabetic
children with NASH showed improvement of fatty liver
at Magnetic Resonance Spectroscopy, and reduction of
ALT level [21]. Subsequent studies however yielded di-
vergent results [22]. The most recent TONIC study [a
large, multicenter RCT evaluating the effect of a 2 year
therapy with Vitamin E (400 IU twice daily) or insulin
sensitizer metformin (500 mg twice daily) or placebo in
173 children with biopsy-confirmed NAFLD] substan-
tiated its scarce effectiveness in lowering serum ALT,
with only marginal effects on hepatic histology [23].
Antioxidants
Oxidative stress is considered another major contributor
to the progression from simple steatosis to NASH by pro-
tecting susceptible components of biological membranes
from lipid peroxidation. Alpha-tocopherol (vitamin E) is
the more extensively studied antioxidant in pediatric
NAFLD. In an open label pediatric trial Lavine et collea-
gues found that Vitamin E (400–1.200 IU/day) may in-
duce a decrease of serum transaminases levels, which was
not related to a reduction in bright liver at ultrasonog-
raphy and BMI values [24]. Other studies comparing the
effect of Vitamin E [25,26] ± ascorbic acid [27] vs. weight
loss alone, however showed that antioxidant treatment
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the double blind RCT study TONIC [23], Vitamin E treat-
ment did not attain a significant and sustained decrease in
ALT levels compared to placebo. However it was better
than placebo in inducing resolution of an histologically
borderline or defined NASH, and in improving hepatocel-
lular ballooning and NAFLD activity histological score.
Cysteamine bitartrate is a recently described potent anti-
oxidant which has been hitherto used only in a small
pediatric NAFLD pilot study with promising effects on re-
duction of transaminase levels [28]. It is currently under
evaluation in a multicenter placebo-controlled clinical trial
(Cysteamine Bitartrate Delayed-Release for the Treatment
of NAFLD in Children) [29].
Other newer antioxidants have shown to represent po-
tential therapeutic tools but have been studied only in
adult NAFLD [1].
Hepatoprotective agents
The hydrophilic bile acid Ursodeoxycholic acid (UDCA)
might antagonize the progression of NAFLD/NASH,
through protection of hepatocytes from bile salts-
mediated mitochondrial injury, antiapoptotic signaling
pathway, and immunomodulatory function [30]. How-
ever, conventional doses of UDCA used in a pilot
pediatric RCT were not effective on ALT levels and
ultrasonographic liver abnormalities [31]. These data
have been confirmed also in several adults studies [32].
Presently it is under verification if (potentially risky [33])
higher doses of UDCA may be necessary [1].
Innovative drugs
Summing up, ordinary NAFLD therapeutic approaches
reviewed above appear most often unsatisfactory or inad-
equate both in adults and in children. Table 1 summarizes
a series of newer treatment targets which have been par-
tially explored in preliminary animal and/or patients stud-
ies and may therefore deserve attention for more
extensive upcoming investigation in adult and pediatric
NAFLD as well.
Probiotics and prebiotics
A growing body of evidence [37] shows that the gut
microbiota controls obesity and visceral fat storage.
Specific variations in gut microbiota in early life mayTable 1 Still not conventional NAFLD treatment targets
Therapeutic target Pharmacolological treatment
Gut-liver axis Probiotics [34]
Dyslipidemia/Insulin
Resistance
Omega-3 DHA (docosahexaenoic acid)
[12]
TNF-α pathway Pentoxifylline and anti-TNF-α [35]
FXRs pathway Agonist of the farnesoid X receptor
(FXR) [36]determine a major risk factor of obesity and its com-
plications later in life [38]. Small intestinal bacterial
overgrowth (SIBO) (a frequent condition in obese indivi-
duals, mainly prompted by slowing of the oro-coecal
transit time) may promote NAFLD progression to non-
alcoholic steatohepatitis by enhancing intestinal perme-
ability and by favoring absorption of endotoxins with
pro-inflammatory and pro-fibrogenetic effects on the
liver [39].
Probiotics are live microorganisms which when con-
sumed in adequate amounts, confer an healthy benefit to
the host [40]. Gut microbiota manipulation with probio-
tics in rodents with fatty liver reduces intestinal inflam-
mation and improves the epithelial barrier function
[41,42]. Therefore, probiotics could represent a new ef-
fective treatment also in NAFLD human patients.
Loguercio and colleagues have shown that probiotics
may reduce NAFLD liver injury and may improve liver
function tests [43]. The Cochrane review [44] and a sub-
sequent pediatric meta-analysis [3] however have high-
lighted that probiotics treatment in patients with NAFLD
and non alcoholic steatohepatitis could not be recom-
mended because of the lack of randomized clinical trials.
More recently a double-blind RCT showed that the treat-
ment with 500 million of Lactobacillus bulgaricus and
Streptococcus thermophiles/day in adults with biopsy-
proven NAFLD causes a reduction of liver transaminases
level [45]. In children, another double-blind RCT study
also showed that obese patients with NAFLD (mean age
10.7 years), treated with Lactobacillus GG (12 billion
CFU/day for 8 weeks), irrespective of changes in BMI z
score and visceral fat, reached a significant decrease (up
to normalization in 80% of cases) in alanine aminotrans-
ferase and in antipeptidoglycan-polysaccharide anti-
bodies (a SIBO marker). TNF-α serum levels, and bright
liver parameters remained quite stable [34].
Prebiotics are non digestible food ingredients that
beneficially affect the host by selectively stimulating
growth and/or modifying metabolic activity of selected
intestinal bacteria [40]. By reducing the risk of obesity
and altering the composition of gut microbiota, prebio-
tics may represent therefore another potential thera-
peutic approach. Studies in obese rats have shown that
prebiotic fibers improve or normalize gut microbiota
dysbiosis by increasing Firmicutes and decreasing Bac-
teroidetes phylae [46]. Gut microbiota modulation is
correlated with an improvement of glucose, energy in-
take, insulin, satiety hormones, hepatic cholesterol, and
triglyceride accumulation [45].
Omega-3 long chain polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) class is present in
several natural foods and includes “essential fatty acids”
like ω-3 and ω-6 acids that the body needs but cannot
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strongly affects several functions of PUFAs. Recent
pharmacological studies in NAFLD animal models and
in adult humans focusing on the effect of oral treatment
with ω-3 fatty acids, demonstrate that they have both
anti-inflammatory and insulin sensitizing properties,
suggesting a potential role in treatment of NAFLD [47].
In NAFLD children ω3-docosahexaenoic acid treatment
for 6 months improved ultrasonographic fatty liver and
insulin sensitivity [12]. Because this treatment is well tol-
erated in pediatric population, DHA deserve further
studies in the management of children with NAFLD.
A surgical approach: bariatric surgery
Bariatric surgery may be proposed for a durable weight
loss in individuals with severe obesity. A study in young
adults (median age = 18.6 years) showed that bariatric
surgery, by causing significant weight loss, leads to an
improvement in clinical and hepatic histological para-
meters [48]. The guidelines for younger ages however
are not yet fully standardized, and studies on safety and
long term efficacy are therefore needed in developing
and transition age [49].
Other potential novel candidate therapeutic targets
A series of other interesting approaches, hitherto
explored only in NAFLD animal models or in few pilot
studies in adults will possibly become in future the ob-
ject of study in pediatric population, as well (Table 1).
TNF-α pathway antagonists
TNF-α and other adipocytokines produced by adipose
tissue are involved in NAFLD progression. Pentoxifyl-
line, a phosphodiesterase inhibitor, exerts immunomo-
dulatory functions by antagonizing the TNF-α pathway.
In adults with NASH, pentoxifylline treatment showed
good tolerability and could decrease serum ALT levels
and improve histological features, as well [35].
Farnesoid X receptor (FXR) agonist
The nuclear bile acid receptor FXR, strongly expressed
in bowel and liver, is probably involved in NAFLD
pathogenesis, by mediating control of lipids and glucose
homeostasis, and controlling bacterial flora growth.
Altogether, these effects may induce reduction of hepatic
inflammation and fibrogenesis, through different
mechanisms. Therefore, recently developed FXR ago-
nists have a potential role in the pharmacological ther-
apy of NAFLD/NASH [36].
Toll-like receptor (TLR) modifiers
TLRs are receptors sensing microbial components of gut
microbiota. A number of recent evidences suggests the
role of SIBO and increased intestinal permeability inNAFLD, by exposing -via portal vein- the liver to an high
load of intestinal noxae including lipopolysaccharide and
other pathogen-associated molecular patterns [50]. Fur-
thermore, TLRs stimulation causes downstream activation
of the inflammatory response. Pro-inflammatory patterns
result in production of cytokines and chemokines impli-
cated in progression from simple steatosis to steatohepati-
tis and fibro-cirrhosis; so therapeutic manipulation of
innate immune system through TLRs modifiers, formerly
evaluated for autoimmune diseases [51], might be a new
potential therapeutic target for pediatric NAFLD, but fur-
ther studies are necessary.
Incretin mimetics and DPP-4 (dipeptidyl peptidase-4)
inhibitors
Glucagon-like peptid-1 (GLP-1) is an incretin secreted
in response to food intake, allotted to multiple functions,
including, the stimulation of glucose-dependent insulin
secretion and inhibition of glucagon release. The enzyme
DPP-4 rapidly degrades circulating GLP-1 (half-life: 1–2
minutes). Recent animal model and NAFLD adults stud-
ies showed an effective role of GLP-1 receptor agonists
resistent to DPP-4 (such as exenatide and liraglutide) or
DPP-4 inhibitors (e.g. some gliptins) as a promising new
therapy in NAFLD for their ability in modulating fatty
acid oxidation, decreasing lipogenesis, and improving
hepatic glucose metabolism [52].
Other pharmacological agents
There are not evidences about the rational for the use of
lipid-lowering agents, angiotensin-converting enzyme
(ACE) inhibitors, and angiotensin-receptor blockers
(ARBs) in treatment of pediatric NAFLD [1].
Discussions
Data here reviewed confirm that weight loss and/or life-
style changes remain the first choice treatment for adult
and pediatric NAFLD, as well. Management strategy for
an obese child with NAFLD should try to attain a grad-
ual weight reduction by a multidisciplinary and long
term therapeutic program combining diet and physical
exercise. Diet prescription should be part of a well-
structured family-based program to enhance self-
motivation and success with diet. Physical exercise
should be encouraged at all levels, since it might allow
better metabolic control, weight reduction or even only
its simple stability. Lack of compliance however remains
a relevant problem, and dietary therapy for obesity gen-
erally fails to achieve its desired target. There is mount-
ing indication that the high rate of relapse from weight
loss during dietary therapy occurs because of complex
compensatory biological adaptations and is not caused
simply by lack of discipline and will power [2].
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standard pharmacological treatments (antioxidants and
insulin-sensitizers) in the large multicenter TONIC
study [23] call for careful re-thinking on the strategies
hitherto pursued for the treatment of NAFLD, both in
adults and in children. Future studies will probably need
resorting to combined tailored treatments, targeting
more than one pathogenetic mechanism.
The recent growing body of evidence on the role of
gut microbiota and gut-liver-axis both in provoking or
worsening obesity itself and/or its related complication
including NAFLD and NASH, calls for robust well
designed studies better focusing the mechanisms con-
trolling possible derangements of the numerous meta-
bolic, toxic, and immunological actors participating to
the gut-liver -axis. At present gut microbiota modulation
by probiotics starts appearing as the most promising tool
due to their safety, tolerability and efficacy, at least in
the preliminary pilot studies hitherto published [34,45].
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